QQQ   444.71 (-0.03%)
AAPL   171.07 (-1.29%)
MSFT   420.54 (-0.21%)
META   487.04 (-1.38%)
GOOGL   150.44 (-0.29%)
AMZN   180.34 (+0.28%)
TSLA   176.60 (-1.80%)
NVDA   907.00 (+0.50%)
NIO   4.63 (-0.86%)
AMD   182.06 (+1.38%)
BABA   72.48 (+1.24%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.21 (-0.78%)
CGC   9.81 (+2.72%)
GE   175.20 (-2.73%)
DIS   122.87 (+1.56%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   67.13 (+0.84%)
XOM   115.63 (+0.57%)
QQQ   444.71 (-0.03%)
AAPL   171.07 (-1.29%)
MSFT   420.54 (-0.21%)
META   487.04 (-1.38%)
GOOGL   150.44 (-0.29%)
AMZN   180.34 (+0.28%)
TSLA   176.60 (-1.80%)
NVDA   907.00 (+0.50%)
NIO   4.63 (-0.86%)
AMD   182.06 (+1.38%)
BABA   72.48 (+1.24%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.21 (-0.78%)
CGC   9.81 (+2.72%)
GE   175.20 (-2.73%)
DIS   122.87 (+1.56%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   67.13 (+0.84%)
XOM   115.63 (+0.57%)
QQQ   444.71 (-0.03%)
AAPL   171.07 (-1.29%)
MSFT   420.54 (-0.21%)
META   487.04 (-1.38%)
GOOGL   150.44 (-0.29%)
AMZN   180.34 (+0.28%)
TSLA   176.60 (-1.80%)
NVDA   907.00 (+0.50%)
NIO   4.63 (-0.86%)
AMD   182.06 (+1.38%)
BABA   72.48 (+1.24%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.21 (-0.78%)
CGC   9.81 (+2.72%)
GE   175.20 (-2.73%)
DIS   122.87 (+1.56%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   67.13 (+0.84%)
XOM   115.63 (+0.57%)
QQQ   444.71 (-0.03%)
AAPL   171.07 (-1.29%)
MSFT   420.54 (-0.21%)
META   487.04 (-1.38%)
GOOGL   150.44 (-0.29%)
AMZN   180.34 (+0.28%)
TSLA   176.60 (-1.80%)
NVDA   907.00 (+0.50%)
NIO   4.63 (-0.86%)
AMD   182.06 (+1.38%)
BABA   72.48 (+1.24%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.21 (-0.78%)
CGC   9.81 (+2.72%)
GE   175.20 (-2.73%)
DIS   122.87 (+1.56%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   67.13 (+0.84%)
XOM   115.63 (+0.57%)
NASDAQ:ARTL

Artelo Biosciences (ARTL) Stock Price, News & Analysis

$1.50
+0.03 (+2.04%)
(As of 11:47 AM ET)
Today's Range
$1.47
$1.52
50-Day Range
$1.36
$1.73
52-Week Range
$1.15
$2.98
Volume
3,608 shs
Average Volume
17,657 shs
Market Capitalization
$4.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.50

Artelo Biosciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
2,052.3% Upside
$32.50 Price Target
Short Interest
Healthy
0.64% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.43mentions of Artelo Biosciences in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.39 out of 5 stars

ARTL stock logo

About Artelo Biosciences Stock (NASDAQ:ARTL)

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for treating breast and prostate cancer, neuropathic and nociceptive pain, and anxiety disorders, including PTSD. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

ARTL Stock Price History

ARTL Stock News Headlines

Recap: Artelo Biosciences Q4 Earnings
Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
Artelo Biosciences Inc ARTL
Artelo Biosciences (ARTL) Gets a Buy from Maxim Group
Artelo Biosciences (ARTL) Gets a Buy from Ladenburg Thalmann & Co.
Artelo Biosciences GAAP EPS of -$3.56
See More Headlines
Receive ARTL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Artelo Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
1/12/2022
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ARTL
Fax
N/A
Employees
5
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$32.50
High Stock Price Target
$60.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+2,081.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-10,080,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.79 per share

Miscellaneous

Free Float
2,659,000
Market Cap
$4.26 million
Optionable
Not Optionable
Beta
1.46
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives


ARTL Stock Analysis - Frequently Asked Questions

Should I buy or sell Artelo Biosciences stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Artelo Biosciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ARTL shares.
View ARTL analyst ratings
or view top-rated stocks.

What is Artelo Biosciences' stock price target for 2024?

2 brokerages have issued 12 month price objectives for Artelo Biosciences' stock. Their ARTL share price targets range from $5.00 to $60.00. On average, they predict the company's share price to reach $32.50 in the next year. This suggests a possible upside of 2,052.3% from the stock's current price.
View analysts price targets for ARTL
or view top-rated stocks among Wall Street analysts.

How have ARTL shares performed in 2024?

Artelo Biosciences' stock was trading at $1.40 at the beginning of the year. Since then, ARTL shares have increased by 7.9% and is now trading at $1.51.
View the best growth stocks for 2024 here
.

Are investors shorting Artelo Biosciences?

Artelo Biosciences saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 20,200 shares, an increase of 9.2% from the February 29th total of 18,500 shares. Based on an average daily volume of 18,100 shares, the short-interest ratio is currently 1.1 days. Approximately 0.6% of the company's stock are sold short.
View Artelo Biosciences' Short Interest
.

When is Artelo Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ARTL earnings forecast
.

How were Artelo Biosciences' earnings last quarter?

Artelo Biosciences, Inc. (NASDAQ:ARTL) announced its earnings results on Wednesday, January, 12th. The company reported ($1.20) earnings per share for the quarter, missing the consensus estimate of ($0.90) by $0.30.

When did Artelo Biosciences' stock split?

Shares of Artelo Biosciences reverse split before market open on Wednesday, August 10th 2022. The 1-15 reverse split was announced on Wednesday, August 10th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, August 10th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Artelo Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Artelo Biosciences investors own include NVIDIA (NVDA), VBI Vaccines (VBIV), Provention Bio (PRVB), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Flexion Therapeutics (FLXN), OPKO Health (OPK), Overstock.com (OSTK), Allena Pharmaceuticals (ALNA) and Advanced Micro Devices (AMD).

How do I buy shares of Artelo Biosciences?

Shares of ARTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ARTL) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners